Best FREE Bookmarking Site, Like RFANDL

10k Google visitor per Day for your website - EXCLUSIVE

Get unlimited lifetime VPN

Make MONEY Online 2018 proved!

loading...

Avatar
Chess5bit

0 Following 0 Followers
1
I.e., it is both cheaper and more efficacious. To our
I.e., it is both cheaper and more efficacious. To our knowledge, there are only three economic studies comparing pregabalin to venlafaxine XR [8,9,33]. NICE [8] performed an economic evaluation based on a network meta-analysis in which the probability of discontinuation due to serious adverse events and the probability of response in patients without those adverse events were estimated. Pregabalin
1
A conservative assumption as the incremental cost of pregabalin compared to
A conservative assumption as the incremental cost of pregabalin compared to venlafaxine XR is higher for the mean doses than for the final doses. The assumption of no discontinuation could also be discussed, as it may be unrealistic, but it makes it possible to differentiate the consequences attributable to the initial treatments from the options that patients could change to. The sensitivity anal
1
A conservative assumption as the incremental cost of pregabalin compared to
A conservative assumption as the incremental cost of pregabalin compared to venlafaxine XR is higher for the mean doses than for the final doses. The assumption of no discontinuation could also be discussed, as it may be unrealistic, but it makes it possible to differentiate the consequences attributable to the initial treatments from the options that patients could change to. The sensitivity anal
1
A conservative assumption as the incremental cost of pregabalin compared to
A conservative assumption as the incremental cost of pregabalin compared to venlafaxine XR is higher for the mean doses than for the final doses. The assumption of no discontinuation could also be discussed, as it may be unrealistic, but it makes it possible to differentiate the consequences attributable to the initial treatments from the options that patients could change to. The sensitivity anal
1
Efficacy and adverse events (and consequent switch) was assumed. The cost-effectiveness
Efficacy and adverse events (and consequent switch) was assumed. The cost-effectiveness acceptability curve derived from the probabilistic sensitivity analysis on the weekly mean percentage changes from baseline in the HAM-A score is shown on Figure 2. It is possible to see that 90 of the cases are below an ICER of 28.2 thousand euros.pregabalin, in which the switch specified by the panel was to
1
Cal study could be a weakness of this analysis, the strength
Cal study could be a weakness of this analysis, the strength derived from the direct comparison should also be acknowledged. Furthermore, the trial considered is the only one comparing flexible doses of pregabalin and venlafaxine XR, which is a more appropriate approach than assuming fixed doses. The placebo-adjusted effect size of pregabalin in this trial is similar to the effect estimated in oth
1
Ence between therapies would be maintained, while in reality it may
Ence between therapies would be maintained, while in reality it may shorten or enlarge. For all other parameters, the impact of the assumptions used in the base case was modest, being important to highlight the non significant increase in the cost perDiscussion and conclusion In this pharmacoeconomic analysis we compared the use of pregabalin and venlafaxine XR in the treatment of generalized anxi
1
Ence between therapies would be maintained, while in reality it may
Ence between therapies would be maintained, while in reality it may shorten or enlarge. For all other parameters, the impact of the assumptions used in the base case was modest, being important to highlight the non significant increase in the cost perDiscussion and conclusion In this pharmacoeconomic analysis we compared the use of pregabalin and venlafaxine XR in the treatment of generalized anxi